These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12297576)

  • 1. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
    Ghalie RG; Edan G; Laurent M; Mauch E; Eisenman S; Hartung HP; Gonsette RE; Butine MD; Goodkin DE
    Neurology; 2002 Sep; 59(6):909-13. PubMed ID: 12297576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
    Ghalie RG; Mauch E; Edan G; Hartung HP; Gonsette RE; Eisenmann S; Le Page E; Butine MD; De Goodkin DE
    Mult Scler; 2002 Oct; 8(5):441-5. PubMed ID: 12356214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
    Kingwell E; Koch M; Leung B; Isserow S; Geddes J; Rieckmann P; Tremlett H
    Neurology; 2010 Jun; 74(22):1822-6. PubMed ID: 20427751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
    Anderlini P; Benjamin RS; Wong FC; Kantarjian HM; Andreeff M; Kornblau SM; O'Brien S; Mackay B; Ewer MS; Pierce SA
    J Clin Oncol; 1995 Nov; 13(11):2827-34. PubMed ID: 7595745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
    BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
    Avasarala JR; Cross AH; Clifford DB; Singer BA; Siegel BA; Abbey EE
    Mult Scler; 2003 Feb; 9(1):59-62. PubMed ID: 12617270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.
    Funch D; Norman H; Wong J; Bennett R; Hillier J; Al-Sabbagh A; Seeger JD
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):448-56. PubMed ID: 20333778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
    Zingler VC; Nabauer M; Jahn K; Gross A; Hohlfeld R; Brandt T; Strupp M
    Eur Neurol; 2005; 54(1):28-33. PubMed ID: 16088176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.
    Cocco E; Sardu C; Gallo P; Capra R; Amato MP; Trojano M; Uccelli A; Marrosu MG;
    Mult Scler; 2008 Nov; 14(9):1225-33. PubMed ID: 18701568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
    Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
    J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
    Swain SM; Whaley FS; Ewer MS
    Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
    Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Le Page E; Leray E; Edan G;
    Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.